Approval for pain reliever for osteoarthritic knees to be delayed
Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.
Those who were waiting for the approval of Synvisc-One will have to wait a little longer. Genzyme Corp., which is applying for approval of the next generation of Synvisc (hylan G-F 20),
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
